Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
CACARA: Cross-Modal Alignment Leveraging a Text-Centric Approach for Cost-Effective Multimodal and Multilingual Learning
arXiv:2512.00496v1 Announce Type: cross Abstract: As deep learning models evolve, new applications and challenges are rapidly emerging. Tasks that once relied on a single modality, such as text, images, or audio, are now enriched by seamless interactions between multimodal data. These connections bridge information gaps: an image can visually materialize a text, while audio can add context to an image. Researchers have developed numerous multimodal models, but most rely on resource-intensive tr
-
cs.AI, q-bio.NC updates on arXiv.org
-
Deep Learning-Based Computer Vision Models for Early Cancer Detection Using Multimodal Medical Imaging and Radiogenomic Integration Frameworks
arXiv:2512.00714v1 Announce Type: cross Abstract: Early cancer detection remains one of the most critical challenges in modern healthcare, where delayed diagnosis significantly reduces survival outcomes. Recent advancements in artificial intelligence, particularly deep learning, have enabled transformative progress in medical imaging analysis. Deep learning-based computer vision models, such as convolutional neural networks (CNNs), transformers, and hybrid attention architectures, can automatic
Deep Learning-Based Computer Vision Models for Early Cancer Detection Using Multimodal Medical Imaging and Radiogenomic Integration Frameworks
-
cs.AI, q-bio.NC updates on arXiv.org
-
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
arXiv:2512.00949v1 Announce Type: cross Abstract: For patients undergoing systemic cancer therapy, the time between clinic visits is full of uncertainties and risks of unmonitored side effects. To bridge this gap in care, we developed and prospectively trialed a multi-modal AI framework for remote patient monitoring (RPM). This system integrates multi-modal data from the HALO-X platform, such as demographics, wearable sensors, daily surveys, and clinical events. Our observational trial is one o
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
-
cs.AI, q-bio.NC updates on arXiv.org
-
A TinyML Reinforcement Learning Approach for Energy-Efficient Light Control in Low-Cost Greenhouse Systems
arXiv:2512.01167v1 Announce Type: cross Abstract: This study presents a reinforcement learning (RL)-based control strategy for adaptive lighting regulation in controlled environments using a low-power microcontroller. A model-free Q-learning algorithm was implemented to dynamically adjust the brightness of a Light-Emitting Diode (LED) based on real-time feedback from a light-dependent resistor (LDR) sensor. The system was trained to stabilize at 13 distinct light intensity levels (L1 to L13), w
A TinyML Reinforcement Learning Approach for Energy-Efficient Light Control in Low-Cost Greenhouse Systems
-
cs.AI, q-bio.NC updates on arXiv.org
-
PhySense: Sensor Placement Optimization for Accurate Physics Sensing
arXiv:2505.18190v4 Announce Type: replace-cross Abstract: Physics sensing plays a central role in many scientific and engineering domains, which inherently involves two coupled tasks: reconstructing dense physical fields from sparse observations and optimizing scattered sensor placements to observe maximum information. While deep learning has made rapid advances in sparse-data reconstruction, existing methods generally omit optimization of sensor placements, leaving the mutual enhancement betwe
PhySense: Sensor Placement Optimization for Accurate Physics Sensing
-
cs.AI, q-bio.NC updates on arXiv.org
-
The AI Productivity Index (APEX)
arXiv:2509.25721v3 Announce Type: replace-cross Abstract: We present an extended version of the AI Productivity Index (APEX-v1-extended), a benchmark for assessing whether frontier models are capable of performing economically valuable tasks in four jobs: investment banking associate, management consultant, big law associate, and primary care physician (MD). This technical report details the extensions to APEX-v1, including an increase in the held-out evaluation set from n = 50 to n = 100 cases
The AI Productivity Index (APEX)
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Exosome-Mediated RUNX3 DNA Delivery for Lung Cancer Therapy
ACS Appl Mater Interfaces. 2025 Dec 1. doi: 10.1021/acsami.5c15987. Online ahead of print.ABSTRACTGene therapy represents a promising strategy for treating lung cancer, with the potential to inhibit the proliferation of cancerous cells and induce apoptosis. However, current gene therapy for lung cancer encounters challenges with delivery, targeting, and safety, such as off-target effects, immune responses, and the necessity for better delivery methods. Here, we introduce gene therapy using the k
Exosome-Mediated RUNX3 DNA Delivery for Lung Cancer Therapy
ACS Appl Mater Interfaces. 2025 Dec 1. doi: 10.1021/acsami.5c15987. Online ahead of print.
ABSTRACT
Gene therapy represents a promising strategy for treating lung cancer, with the potential to inhibit the proliferation of cancerous cells and induce apoptosis. However, current gene therapy for lung cancer encounters challenges with delivery, targeting, and safety, such as off-target effects, immune responses, and the necessity for better delivery methods. Here, we introduce gene therapy using the key regulator in lung adenocarcinoma, runt-related transcription factor 3 (RUNX3), within exosomes (Exos), which are known for their biocompatibility and ability to selectively target cancer cells. We packaged the RUNX3 plasmid DNA into human exosomes (hExo-Rs), designed to target and induce apoptosis in cancer cells, resulting in a viability decrease to 43.3%. Normal fibroblasts remained viable at 96.0%, confirming the safety of hExo-Rs for future therapies. We delivered hExo-Rs to cancer spheroids, examined their effects, and found that cytokines from treated cells promote M1 macrophage polarization, emphasizing their potential for immunotherapy. We developed a hydrogel platform for the targeted 14-day release of RUNX3 pDNA by attaching hExo-Rs to gelatin using microbial transglutaminase, which enables the selective decrease in cancer cell viability and confirms apoptosis. Our demonstration of RUNX3 gene therapy with Exos presents selective anticancer effectiveness and the promise of clinical use through localized, sustained release using the hydrogel.
PMID:41325015 | DOI:10.1021/acsami.5c15987
-
npj Digital Medicine
-
The role of digital twins in P4 medicine: A paradigm for modern healthcare
npj Digital Medicine, Published online: 01 December 2025; doi:10.1038/s41746-025-02115-xThe role of digital twins in P4 medicine: A paradigm for modern healthcare
The role of digital twins in P4 medicine: A paradigm for modern healthcare
npj Digital Medicine, Published online: 01 December 2025; doi:10.1038/s41746-025-02115-x
The role of digital twins in P4 medicine: A paradigm for modern healthcare-
MRD
-
DNA-Based Liquid Biopsy for Evaluating Surgical and Postsurgical Outcomes in Gynecologic Malignancies: A Systematic Review
J Clin Lab Anal. 2025 Dec 1:e70139. doi: 10.1002/jcla.70139. Online ahead of print.ABSTRACTINTRODUCTION: DNA-based liquid biopsies, including circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA), are emerging as minimally invasive biomarkers for monitoring surgical and postsurgical outcomes in gynecologic malignancies. These tools offer the potential to guide early intervention, refine risk stratification, and improve prognostic accuracy. This systematic review aimed to assess the clinical ut
DNA-Based Liquid Biopsy for Evaluating Surgical and Postsurgical Outcomes in Gynecologic Malignancies: A Systematic Review
J Clin Lab Anal. 2025 Dec 1:e70139. doi: 10.1002/jcla.70139. Online ahead of print.
ABSTRACT
INTRODUCTION: DNA-based liquid biopsies, including circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA), are emerging as minimally invasive biomarkers for monitoring surgical and postsurgical outcomes in gynecologic malignancies. These tools offer the potential to guide early intervention, refine risk stratification, and improve prognostic accuracy. This systematic review aimed to assess the clinical utility of DNA-based liquid biopsies in evaluating recurrence, surgical success, and preoperative diagnosis in gynecologic cancers.
METHODS: A systematic review was conducted in accordance with PRISMA guidelines, covering studies published from 2017 to 2025. Literature searches were performed in PubMed, Scopus, and Web of Science. A total of 32 eligible observational studies involving 3210 patients with ovarian, endometrial, uterine, and other gynecologic malignancies were included. Study quality was assessed using the Newcastle-Ottawa Scale (NOS).
RESULTS: The studies showed a broad geographic and methodological diversity, with a median NOS score of 7. CtDNA and cfDNA demonstrated promise in three key areas: (1) Recurrence prediction-postoperative ctDNA positivity was associated with higher relapse rates and reduced disease-free survival; (2) Monitoring surgical outcomes and treatment response-ctDNA dynamics more accurately reflected tumor burden than traditional markers like CA125; (3) Preoperative diagnostic support-cfDNA methylation profiling and cfDNA/CA125 models enhanced malignancy detection and risk stratification. Ovarian and endometrial cancers were most frequently studied.
CONCLUSIONS: DNA-based liquid biopsies show strong potential in perioperative care for gynecologic cancers. Their integration into clinical workflows could improve the detection of minimal residual disease and inform individualized surgical planning.
PMID:41327898 | DOI:10.1002/jcla.70139